Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
April 5th, 2024
Here, we detail a straightforward live imaging approach for quantifying the sensitivity of patient-derived tumor organoids to ionizing radiation.
Clonogenic assays are routinely employed to measure the radiation sensitivity of cultured human and mouse cancer cells, and they are considered the gold standard for assessing reproductive cell death induced by radiation, which is more relevant to tumor response to radiation therapy than other measures of cell death quantified using short-term techniques. Clonogenic assays were designed for cells that grew in two-dimensional cultures, which do not recapitulate cell-cell interactions and interactions with the cellular matrix as they occur in the tumor. Patient-derived tumor organoids have emerged as tumor models that at least in part circumvent such limitation.
Conventional clonogenic assays cannot be employed as such to assess the radiosensitivity of patient-derived tumor organoids. Here, we detail the technique that harnesses live imaging of breast cancer patient-derived tumor organoids to monitor the organoid forming efficacy and growth rate after exposure to ionizing irradiation versus non-irradiated treatment. In the era of personalized medicine, assessing the sensitivity of patient-derived models is of the utmost importance as it provides the information that is required to design and personalize treatment strategies.
In the future, we will be addressing the role of the immune cells that are present in the tumor in modulating the response of PDTO to radiations therapy.
Overview
This study presents a live imaging technique to assess the sensitivity of patient-derived tumor organoids to ionizing radiation. This method allows for a more accurate evaluation of tumor responses compared to traditional clonogenic assays.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Radiation Therapy
Background
- Clonogenic assays are the gold standard for measuring radiation sensitivity.
- These assays are limited by their reliance on two-dimensional cell cultures.
- Patient-derived tumor organoids provide a more relevant model for studying tumor responses.
- Conventional assays cannot be applied to these organoids.
Purpose of Study
- To develop a method for assessing the radiosensitivity of patient-derived tumor organoids.
- To enhance the understanding of tumor responses to ionizing radiation.
- To support personalized treatment strategies in oncology.
Methods Used
- Live imaging of breast cancer patient-derived tumor organoids.
- Monitoring organoid forming efficacy post-irradiation.
- Comparing growth rates of irradiated versus non-irradiated organoids.
- Utilizing patient-derived models for personalized medicine applications.
Main Results
- The live imaging technique successfully quantified organoid responses to radiation.
- Significant differences in growth rates were observed between treated and untreated organoids.
- This method provides insights into the radiosensitivity of tumors.
- Results support the potential for personalized treatment approaches.
Conclusions
- The developed technique offers a novel approach to assess tumor organoid sensitivity.
- Live imaging can replace traditional clonogenic assays for patient-derived models.
- This study contributes to the field of personalized medicine in oncology.
Frequently Asked Questions
Executive Industry Relevance
Quantifying radiosensitivity in patient-derived tumor organoids (PDTOs) addresses a critical gap in translational oncology by enabling functional assessment of tumor response in clinically relevant 3D models. This live imaging adaptation of clonogenic assays enhances predictive confidence for radiation therapy outcomes and supports risk-adjusted portfolio decisions in early discovery and preclinical research. The approach directly informs personalized treatment strategies and mechanistic de-risking for oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of radiosensitivity in disease-relevant 3D tumor models.
- Supports mechanistic de-risking by quantifying stem-like cell survival post-irradiation.
- Improves predictive confidence for target validation in radiation response pathways.
- Facilitates portfolio triage by distinguishing tumor subtypes with differential radiosensitivity.
Screening & Assay Development
- Establishes validated, quantitative readouts for organoid-forming efficiency and growth rate post-irradiation.
- Enables reproducible, scalable live imaging workflows for compound or radiation screening.
- Supports assay standardization for cross-study and cross-model comparisons.
- Prepares robust biological systems for downstream screening and mechanistic studies.
Translational & Preclinical Research
- Aligns preclinical models with patient-specific tumor biology for translational continuity.
- Enables risk-adjusted advancement decisions based on functional radiosensitivity data.
- Supports biomarker discovery by correlating organoid response with clinical outcomes.
- Provides a platform for future integration of immune components in response studies.
Pipeline & Workflow Integration
This live imaging assay positions within the discovery-to-preclinical continuum, bridging early mechanistic studies and translational validation for radiation response in oncology.
- Discovery Biology: Quantifies radiosensitivity and stem-like cell survival to clarify therapeutic hypotheses.
- Screening: Delivers standardized, quantitative outputs for assay readiness and reproducibility.
- Analytics: Provides time-lapse imaging data for robust statistical comparison of irradiated versus control conditions.
- Translational Research: Maintains disease relevance by using patient-derived organoids reflective of clinical heterogeneity.
- Enterprise Reuse: Offers a reusable platform adaptable to diverse tumor types and research questions.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in radiation response studies.
- Operational Value: Enhances standardization, reproducibility, and scalability of radiosensitivity assays.
- Strategic Value: Informs go/no-go decisions and capital allocation by providing functional data on tumor radiosensitivity.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets based on functional response metrics.
Implementation Considerations
- Requires expertise in 3D organoid culture and live imaging analysis.
- Demands access to advanced imaging instrumentation and analytical infrastructure.
- Necessitates cross-team standardization of assay protocols and data interpretation.
- May require adaptation for different tumor types or integration of additional cellular components.
- Dependent on the ability to generate and maintain viable patient-derived organoids.
